Hematopoietic cell transplantation for mantle cell lymphoma: Predictive value of pretransplant positron emission tomography/computed tomography and bone marrow evaluations for outcomes

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 2, 2014, Pages 114-121

  Magnusson, Erik ^a   Cao, Qing ^a   Linden, Michael A ^b   Frolich, Jerry ^a   Anand, Vidhu ^a   Burns, Linda J ^a   Bachanova, Veronika ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

Allogeneic transplantation; Autologous transplantation; Minimal residual disease; MIPI score; PET scan

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; PREDNISONE; RITUXIMAB; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ALLOTRANSPLANTATION; ARTICLE; AUTOTRANSPLANTATION; BONE MARROW EXAMINATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CELL TRANSPLANTATION; CHEMOSENSITIVITY; COMORBIDITY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEMATOPOIETIC CELL TRANSPLANTATION; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PET-CT SCANNER; PREDICTIVE VALUE; RECURRENCE RISK; COMPUTER ASSISTED TOMOGRAPHY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, MANTLE-CELL; MULTIMODALITY CANCER THERAPY; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PROCEDURES; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STATISTICS AND NUMERICAL DATA; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW EXAMINATION; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OUTCOME ASSESSMENT (HEALTH CARE); POSITRON-EMISSION TOMOGRAPHY; PREOPERATIVE PERIOD; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TOMOGRAPHY, X-RAY COMPUTED; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84896392227     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.10.007     Document Type: Article

References (31)

1. A. Herrmann, E. Hoster, and T. Zwingers et al. Improvement of overall survival in advanced stage mantle cell lymphoma J Clin Oncol 27 2009 511 518.
2. M. Dreyling, H.C. Kluin-Nelemans, and S. Bea et al. Update on the molecular pathogenesis and clinical treatment of mantle cell lymphoma: report of the 11th annual conference of the European Mantle Cell Lymphoma Network Leuk Lymphoma 54 2013 699 707.
3. J.E. Romaguera, L.E. Fayad, and L. Feng et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma Br J Haematol 150 2010 200 208.
4. C.H. Geisler, A. Kolstad, and A. Laurell et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group Blood 112 2008 2687 2693.
5. H. Schulz, J.F. Bohlius, and S. Trelle et al. Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis J Natl Cancer Inst 99 2007 706 714.
6. G. Lenz, M. Dreyling, and E. Hoster et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG) J Clin Oncol 23 2005 1984 1992.
7. C.S. Tam, R. Bassett, and C. Ledesma et al. Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma Blood 113 2009 4144 4152.
8. S. Le Gouill, N. Kroger, and N. Dhedin et al. Reduced-intensity conditioning allogeneic stem cell transplantation for relapsed/refractory mantle cell lymphoma: a multicenter experience Ann Oncol 23 2012 2695 2703.
9. M. Tomblyn, C. Brunstein, and L.J. Burns et al. Similar and promising outcomes in lymphoma patients treated with myeloablative or nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation Biol Blood Marrow Transplant 14 2008 538 545.
10. E. Hoster, M. Dreyling, and W. Klapper et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma Blood 111 2008 558 565.
11. L.E. Damon, J.L. Johnson, and D. Niedzwiecki et al. Immunochemotherapy and autologous stem-cell transplantation for untreated patients with mantle-cell lymphoma: CALGB 59909 J Clin Oncol 27 2009 6101 6108.
12. L.E. Budde, K.A. Guthrie, and B.G. Till et al. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation J Clin Oncol 29 2011 3023 3029.
13. H. Liu, J.L. Johnson, and G. Koval et al. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909 Haematologica 97 2012 579 585.
14. S. Bottcher, M. Ritgen, and S. Buske et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations Haematologica 93 2008 551 559.
15. M.E. Juweid, S. Stroobants, and O.S. Hoekstra et al. Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25 2007 571 578.
16. S. Gill, M. Wolf, and H.M. Prince et al. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma Clin Lymphoma Myeloma 8 2008 159 165.
17. P.J. Hosein, V.H. Pastorini, and F.M. Paes et al. Utility of positron emission tomography scans in mantle cell lymphoma Am J Hematol 86 2011 841 845.
18. J.B. Cohen, N.C. Hall, and A.S. Ruppert et al. Association of pre-transplantation positron emission tomography/computed tomography and outcome in mantle cell lymphoma Bone Marrow Transplant 48 2013 1212 1217.
19. A.R. Mato, J. Svoboda, and T. Feldman et al. Post-treatment (not interim) positron emission tomography-computed tomography scan status is highly predictive of outcome in mantle cell lymphoma patients treated with R-HyperCVAD Cancer 118 2012 3565 3570.
20. B.D. Cheson, B. Pfistner, and M.E. Juweid et al. Revised response criteria for malignant lymphoma J Clin Oncol 25 2007 579 586.
21. J.E. Coad, D.J. Olson, and D.R. Christensen et al. Correlation of PCR-detected clonal gene rearrangements with bone marrow morphology in patients with B-lineage lymphomas Am J Surg Pathol 21 1997 1047 1056.
22. N. Mitha, and R.C. McGlennen Methods to detect clonal gene rearrangements in lymphomas and leukemias Methods Mol Med 49 2001 189 209.
23. E.L. Kaplan Nonparametric estimation from incomplete observations J Amer Statist Assn 53 1958 457 481.
24. D.Y. Lin Non-parametric inference for cumulative incidence functions in competing risks studies Stat Med 16 1997 901 910.
25. C.H. Geisler, A. Kolstad, and A. Laurell et al. Nordic MCL2 trial update: six-year follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: still very long survival but late relapses do occur Br J Haematol 158 2012 355 362.
26. R. Delarue, C. Haioun, and V. Ribrag et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte Blood 121 2013 48 53.
27. C. Pott, E. Hoster, and M.H. Delfau-Larue et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study Blood 115 2010 3215 3223.
28. A. Dodero, R. Crocchiolo, and F. Patriarca et al. Pretransplantation [18-F]fluorodeoxyglucose positron emission tomography scan predicts outcome in patients with recurrent Hodgkin lymphoma or aggressive non-Hodgkin lymphoma undergoing reduced-intensity conditioning followed by allogeneic stem cell transplantation Cancer 116 2010 5001 5011.
29. J.R. Lambert, J.B. Bomanji, and K.S. Peggs et al. Prognostic role of PET scanning before and after reduced-intensity allogeneic stem cell transplantation for lymphoma Blood 115 2010 2763 2768.
30. M.B. Maris, B.M. Sandmaier, and B.E. Storer et al. Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma Blood 104 2004 3535 3542.
31. M. Hamadani, W. Saber, and K.W. Ahn et al. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research Biol Blood Marrow Transplant 19 2013 625 631